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ABSTRACT
Background: Recombinant human hyaluronidase (rHuPH20) (150 U) is ap-
proved by the US Food and Drug Administration to facilitate subcutaneous fluid 
administration in adults and children.
Objective: This Phase IV, double-blind, randomized pilot study was designed 
to compare the tolerability, flow rate, and safety profile of subcutaneous infusions 
of normal saline (NS) and lactated Ringer’s (LR) solutions following subcutaneous 
administration of rHuPH20. 
Methods: Healthy volunteers received 1 mL rHuPH20 (150 U) in each thigh, 
followed by simultaneous gravity-driven subcutaneous infusions of 500 mL of LR 
solution into 1 thigh and NS solution into the contralateral thigh. Subjects rated 
infusion-site discomfort in each thigh using a 100-mm (0 = no pain to 100 = most 
severe pain) visual analog scale (VAS) at baseline (ie, after catheter placement/ 
rHuPH20 injection and just prior to the start of the infusions) and at the following 
times: after infusion of 250 mL, after infusion of 500 mL (end of infusion), and when 
thigh circumference returned to within 5% of baseline. Adverse events (AEs) were 
recorded throughout the study. The primary tolerability end point was the maximal 
increase from baseline in infusion-site discomfort on the VAS. Secondary end points 
included infusion flow rate, change in thigh circumference, subject preference for left- 
versus right-thigh infusion, and safety profile measures.
Results: Fifteen subjects (14 women, 1 man; mean age, 41 years [range, 20– 
60 years]) were included in the study. Mean (SD) maximal increase from baseline VAS 
pain score was significantly greater with NS solution than with LR solution (20.0 
[19.4] vs 9.4 [18.3] mm, respectively; P = 0.005). Mean infusion flow rate was 
not significantly different between the NS and LR solutions (384.1 [118.1] vs 
395.8 [132.8] mL/h). No significant differences between solutions were observed in 
mean maximal change in thigh circumference (5.2% [1.6%] vs 5.3% [1.5%]). All subjects 
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expressed global preference for LR infusion over NS infusion. All subjects experienced 
≥1 AE; the majority of AEs were mild, localized infusion-site reactions. Of all AEs 
(regardless of their relationship to study drug or procedure), 81% were mild injection-
site reactions that were similar in nature for the NS and LR solutions. Although the 
types of mild local AEs were similar for the 2 infusions, they were numerically more 
common with NS infusions (15 subjects [100%]) than with LR infusions (9 subjects 
[60%]). For the NS and LR solutions, the most frequent infusion-site AEs were pain 
(67% vs 40%, respectively), erythema (47% vs 13%), and irritation (27% vs 20%).
Conclusions: This small pilot study found that the mean maximal increase 
from baseline in self-assessed pain VAS scores was statistically significantly higher 
with NS solution than LR solution. In addition, all subjects preferred LR solution to 
NS solution, and the incidence of some infusion-site AEs was numerically greater 
with NS solution. Although the VAS score indicated a statistically significant differ-
ence in tolerability favoring LR, the modest changes from baseline suggest both solu-
tions were generally well tolerated and support the use of both NS and LR, as appro-
priate, for rHuPH20-facilitated subcutaneous isotonic fluid infusion in healthy adults. 
These results need to be confirmed in larger, controlled clinical studies. (Curr Ther Res 
Clin Exp. 2009;70:421–438) © 2009 Excerpta Medica Inc.
Key words: subcutaneous infusion, fluid therapy, hyaluronidase, rehydration 
solutions, isotonic solution.
INTRODUCTION
While intravenous therapy has long been the standard of care for parenteral 
rehydration,1 placement of an intravenous catheter requires specialized skills.2–4 Sub-
cutaneous fluid administration is an alternative to intravenous hydration in appropri-
ately selected patients. Clinical experience has demonstrated its tolerability and effi-
cacy in restoring fluid volumes in adults with mild to moderate dehydration.5–9 
Clinical studies suggest that subcutaneous fluid replacement is as effective as intrave-
nous rehydration therapy for the treatment of mild to moderate dehydration in elderly 
patients.7,8,10–12 The technique of subcutaneous infusion is straightforward; catheters 
can be quickly inserted by personnel without advanced skills.1,6 Furthermore, subcu-
taneous infusion may be associated with fewer complications and lower costs than 
intravenous fluid administration.7,11–15 The ease of subcutaneous administration may 
reduce overall health care costs by allowing patients to receive parenteral fluids out-
side the hospital (eg, in the home or a hospice setting).1,9,13,14,16–18 Potential disad-
vantages of subcutaneous hydration include limitations to its use in severe dehydra-
tion and shock, in any situation requiring >3 L fluid administration over 24 hours, or 
in which careful fluid titration is required, such as heart failure or renal failure.19
Clinical trials have shown that absorption of subcutaneously administered isotonic 
fluids and drugs can be accelerated by concomitant administration of the enzymatic 
spreading agent hyaluronidase.20–22 By depolymerizing hyaluronan, a viscous compo-
nent of the interstitial space that impedes the diffusion of injected substances, hyal- 
uronidase temporarily increases tissue permeability and speeds the uptake of fluids 
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into the systemic circulation.20,21,23,24 Studies conducted in the 1940s and 1950s 
found that animal-derived hyaluronidase accelerated subcutaneous fluid absorption to 
a rate that was 1.6- to 3.3-fold greater than with subcutaneous fluids alone and was 
associated with fewer complications.25–27 More recent evidence from a study compar-
ing pharmacokinetics of a radioisotope (tritium) infused in normal saline (NS) over 
3 hours via subcutaneous versus intravenous administration confirms that hyaluronidase-
facilitated subcutaneous fluid absorption is rapid and comparable to absorption with 
intravenous fluid administration.22
Historical reports of allergic reactions and rare cases of anaphylaxis have limited the 
use of animal-derived hyaluronidase.28,29 In contrast, clinical data indicated that a 
single intradermal test injection of recombinant human hyaluronidase (rHuPH20), 
that has up to 100 times greater purity than the reference standard, animal-derived 
form based on enzymatic activity,30 showed no allergenic reactions in healthy adults. 
Subcutaneous administration of 150 U of rHuPH20 was well tolerated in adult vol-
unteers and hospice patients.20,30,31
rHuPH20* 150 U is approved by the US Food and Drug Administration to facili-
tate subcutaneous fluid administration in adults and children.32 In a previously 
published clinical trial in 54 healthy volunteers (INFUSE-LR study20), rHuPH20- 
facilitated subcutaneous administration of lactated Ringer’s (LR) solution was found 
to be effective and well tolerated. In a recent series of case reports, rHuPH20 was 
found to be effective and well tolerated when used in conjunction with standard hy-
dration fluids, including NS, 5% dextrose in NS (D5NS), 5% dextrose in 1/2NS 
(D51/2NS), and LR solutions.
31
Because blood acts as a buffer, pH and osmolarity differences that are considered to 
be of little consequence when solutions are administered intravenously may result in 
differences in tolerability during subcutaneous administration, when the buffering 
capacity of the surrounding tissue is limited. Whereas NS solution has a mean pH of 
5.0 (range, 4.5–7.0) and osmolarity of 308 mOsm/L, LR solution is more physiologi-
cally neutral, with a mean pH of 6.5 (range, 6.0–7.5) and osmolarity of 273 mOsm/L, 
based on the manufacturers’ specifications. These differences suggest possible varia-
tions in tolerability when NS and LR solutions are administered by subcutaneous 
infusion. The primary objective of this study was to compare, in a controlled clinical 
trial design, the relative tolerability of rHuPH20-facilitated subcutaneous adminis-
tration of NS and LR solutions in healthy adults.
SUBJECTS AND METHODS
Healthy volunteers were enrolled in this Phase IV, single-center, prospective, double-
blind, randomized, within-subject controlled, 2-stage pilot study. Stage 1 compared 
the tolerability, infusion flow rates, and safety profiles of NS and LR solutions admin-
istered by subcutaneous infusion preceded by rHuPH20 administration. Stage 2, a 
* Hylenex™, manufactured for Halozyme Therapeutics, Inc., San Diego, California by Baxter Healthcare Corporation, 
Deerfield, Illinois.
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comparison of NS and buffered NS, was to be conducted only if LR and NS differed by 
≥25 mm in mean maximal pain score on a 100-mm visual analog scale (VAS) in stage 1.
In stage 1, each subject received rHuPH20 1 mL (150 U) by subcutaneous injec-
tion in each thigh followed immediately by simultaneous gravity-driven subcutane-
ous infusions of 500 mL of NS solution in 1 thigh and 500 mL of LR solution in the 
contralateral thigh.
The protocol was approved by an institutional review board (IntegReview, Austin, 
Texas) and each subject signed an approved informed-consent form before study 
participation.
Inclusion and Exclusion Criteria
Eligible subjects included male and female volunteers aged 18 to 60 years who had 
intact normal skin (ie, without potentially obscuring tattoos, pigmentation, or lesions 
in the areas intended for infusion) and normal vital signs and clinical laboratory 
findings.
Subjects were excluded if they had lower-extremity edema or any lower-extremity 
pathology that might interfere with the study outcome (eg, cellulitis, lymphatic dis-
order, prior surgery, preexisting pain syndrome, or previous inguinal lymph node 
dissection); rales on lung auscultation; a history of cardiovascular disease; known al-
lergy to hyaluronidase or any other ingredient in the formulation; or known allergy to 
bee or vespid (wasp) venom. Female subjects could not be pregnant or breastfeeding. 
Subjects were excluded if they had participated in a study of an investigational drug 
or device within 30 days of the start of the study.
Screening
During the week preceding the study treatment phase, written informed consent, 
a medical history, and a list of current medications were obtained from each subject. 
Screening assessments included a complete physical examination, measurements of 
vital signs (ie, blood pressure and heart and respiratory rates), and clinical laboratory 
tests (ie, metabolic panel). Women of child bearing age were required to have a nega-
tive urine or serum pregnancy test within 7 days of study infusion. All subjects were 
instructed to refrain from drinking fluids for 12 hours before entering the treatment 
phase, except for sips of water required to take medications.
Randomization and Blinding
Each subject enrolled in the study was assigned the next sequential subject identifica-
tion number from a randomization code that designated, in a double-blind fashion, 
which thigh would receive NS solution and which would receive LR solution in stage 
1. The randomization codes were generated using a random, permuted block design, 
with a block size of 2. The randomization code was kept in a secure area in the pharmacy 
by the research pharmacist so that the rest of the investigational staff, the study subjects, 
and the sponsor could not access the code until after the entire study had been unblinded 
following final data collection for the last subject. Infusion bags were disguised and la-
beled “left” and “right,” according to each subject’s randomization code.
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Outcome Measures
The primary end point was the subject’s self-assessment of discomfort at the infu-
sion site using a VAS that ranged from 0 mm (no pain) to 100 mm (most severe 
pain). The VAS was scored once for each leg at baseline (ie, after catheter placement/ 
rHuPH20 injection and immediately before the start of the infusions) and was re-
peated at the following time points: after infusion of 250 mL, after infusion of 500 mL 
(the end of the infusion), and when thigh circumference returned to within 5% of 
baseline. At each time point, the subject was asked in a uniform manner, by the same 
study personnel, to score the highest level of discomfort experienced in the interval 
since the previous VAS scoring.
Secondary end points comprised the following: (1) the mean infusion flow rate 
(mL/h) based on the time to infuse up to 500 mL of solution; (2) the change in thigh 
circumference at the infusion site; (3) the time from the beginning of the infusion 
until the thigh circumference returned to within 5% of the baseline circumference; 
and (4) the subject’s global preference for infusion (overall blinded preference for infu-
sion solution, recorded as left vs right thigh). Digital photographs of the infusion sites 
were taken for descriptive purposes; adverse events (AEs), physical findings, and vital 
signs were evaluated to monitor safety.
Infusion Protocol
On the treatment day (day 1), all subjects were given a targeted physical examina-
tion to evaluate the infusion sites, check for edema, and perform lung auscultation for 
rales. After the subjects assumed a comfortable, semirecumbent position, study staff 
placed a 24-gauge angiocatheter with attached Y-port into the subcutaneous space of 
each anterior thigh midway between the anterior iliac crest and the cephalad border 
of the patella at a 30° angle. rHuPH20 1 mL (150 U) was injected simultaneously by 
slow push into each Y-port, followed immediately by simultaneous 500-mL SC in-
fusions of NS solution in one thigh and LR solution in the other thigh administered 
in a randomized, double-blind fashion. The solutions were delivered by gravity-driven 
infusion with the meniscus of each 500-mL bag placed 100 cm above the respective 
angiocatheter site. Intolerable infusion-site discomfort required 1 of 3 possible actions: 
infusion rate reduction, interruption of the infusion until the discomfort subsided, or 
premature infusion discontinuation.
Baseline thigh circumference measurements at the level of the angiocatheters (using 
a flexible measuring tape) and photographs of the infusion site were taken immedi-
ately after catheter placement, just before rHuPH20 injection. These measurements 
were repeated mid-infusion (after 250 mL had been infused) and at the end of infusion 
(after 500 mL had been infused) for each solution. The angiocatheters were removed 
at the end of each infusion, and thigh circumference was measured every 30 minutes 
until each thigh had returned to within 5% of its baseline value. Photographs were 
repeated for each thigh after the corresponding final circumference measurement.
To determine infusion flow rate, the amount of fluid infused was assessed from the 
weight of the infusion bag, fluid, and tubing at designated time points using a hang-
ing scale with a digital weight display. A 1-g change in weight was considered equiva-
Current Therapeutic Research
426
lent to a 1-mL change in infusion solution volume. Weights were recorded immedi-
ately before subcutaneous infusion, every minute for the first 10 minutes of the 
infusion, every 5 minutes for the next 30 minutes, and every 15 minutes thereafter 
until 500 mL had been infused.
Safety was determined by assessment of AEs, physical examination, infusion-site as-
sessment, lung auscultation for rales, and measurement of vital signs. AEs were assessed 
continually throughout the study by the clinical investigator. The relationship of AEs 
to study drug and procedure was assessed according to guidelines available to the inves-
tigator on electronic case-report forms. Infusions were discontinued if there were any 
signs or symptoms of unacceptable fluid overload. Subjects were discharged from the 
clinic on day 1 after completing the infusions and all protocol-specified assessments.
Follow-Up
On the day after infusion, subjects returned to the clinic for a follow-up safety 
evaluation that included AE assessment; review of concomitant medications; measure-
ments of vital signs and weight; and a targeted physical examination focusing on infu-
sion sites, lung auscultation for rales, positive responses from a complete review of 
body systems, and follow-up of any previous findings. Approximately 7 days postinfu-
sion, a telephone call was made to each subject to review concomitant medications and 
to inquire about AEs.
Statistical Analysis
The sample size of 15 subjects chosen for this trial, which was deemed adequate for 
a pilot study, was intended to explore possible differences in tolerability (based on 
observed mean and 95% CIs) when comparing subcutaneous infusions but was not 
necessarily powered to show a statistically significant difference between solutions. 
The primary statistical analysis for this study compared the maximal postbaseline 
increase in subject-assessed discomfort based on VAS scores for NS and LR infusions. 
The pairwise comparison of mean maximal postbaseline increase in VAS scores for NS 
infusion versus LR infusion was performed using the Wilcoxon signed rank test, 
which was selected as the appropriate test for comparison of 2 related samples consist-
ing of nonparametric data.33
Additional secondary analyses included paired analyses of the mean infusion flow 
rate (mL/h) derived from the time to infuse 500 mL of solution and the change in 
thigh circumference at the infusion site. Descriptive statistics were calculated for the 
time required for the thigh circumference to return to within 5% of baseline circum-
ference and the subjects’ global preference for infusion solution, as indicated by selec-
tion of either the left thigh or the right thigh. Digital photographic images of the 
infusion sites were assessed as a descriptive parameter.
All safety data (AEs, physical examination findings, and vital signs) were summa-
rized using descriptive statistics. The study was not powered to demonstrate a differ-
ence in safety between treatment groups. AEs were tabulated according to severity; 
localization to the infusion site; relatedness to the study drug (rHuPH20); and, sepa-
rately, relatedness to the NS or LR infusion procedure.
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RESULTS
Subjects
Twenty-five subjects were assessed for eligibility and signed an informed-consent form; 
7 subjects were excluded during screening and 3 were screened as alternates but were not 
enrolled. Among the 7 subjects excluded during screening, 6 did not meet inclusion cri-
teria and 1 withdrew consent. The 15 enrolled subjects (14 women and 1 man) completed 
both infusions and were included in all analyses (Figure 1). Fourteen subjects were white 
and 1 was black. The subjects’ mean age was 41 years (range, 20–60 years), mean (SD) 
height was 158.2 (28.5) cm, and mean weight was 74.0 (13.5) kg.
Primary End Point: Self-Assessment of Discomfort
Baseline VAS scores ranged from 0 to 33 mm; the maximal increase from baseline 
in VAS score is presented for each subject in Figure 2. The self-assessed level of dis-
comfort varied from subject to subject (postbaseline absolute VAS scores ranged from 
0 to 61 mm for NS and LR) but remained tolerable for both infusion solutions for all 
subjects, with no subject prematurely discontinuing either infusion. In general, sub-
Subjects screened
(N = 25)
Alternatives
screened, but not enrolled
(n = 3)
Subjects randomized
(n = 15)
Screening failures (n = 7)*
Elevated BP (2)
Elevated ALT (2)
Skin pigmentation (1)
Neurofibromatosis (1)
Rhonchi (1)
Withdrew consent (1)
Stage 1
(n = 15)
Completed both
double-blind infusions
(n = 15)
Stage 2
(n = 0)
Protocol criteria for
proceeding to stage 2
not satisfied
Figure 1.  Subject disposition. BP = blood pressure; ALT = alanine aminotransferase. 
*One subject failed the screening for 2 reasons.
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jects who reported a maximal postbaseline VAS increase >25 mm did so for both infu-
sions. One subject demonstrated an unusual pattern, reporting an increase in pain 
during the NS infusion (maximal increase of 34 mm from a baseline of 9 mm) but a 
decrease in pain during the LR infusion (from a baseline of 33 mm). The subject’s 
baseline VAS score for the LR thigh was higher than all postbaseline scores, including 
the maximum absolute postbaseline score of 20 mm, which resulted in a negative 
value (–13 mm) for the maximal increase score.
The mean (SD) maximal increase from baseline in VAS score was statistically 
significantly greater for NS solution compared with LR solution (20.0 [19.4] vs 
9.4 [18.3] mm; P = 0.005, by Wilcoxon signed rank test). The absolute postbaseline 
maximal VAS score was 25.6 (21.4) mm for NS solution and 12.7 (17.6) mm for 
LR solution.
A blinded interim analysis used a similar comparison. The paired infusions for each 
subject were categorized as more pain and less pain, and the maximum possible differ-
ence in mean maximal increase in VAS score between NS and LR infusions was deter-
mined to be 10.6 mm, below the 25-mm threshold necessary for study continuation. 
As a result, stage 2 of the study was not conducted.
Secondary End Points
Infusion Flow Rate
The mean (SD) flow rates for NS and LR infusions (derived from the time to infuse 
500 mL of solution) did not differ significantly (384.1 [118.1] and 395.8 [132.8] mL/h, 
respectively).
Individual infusion flow rates were close to linear over time and were similar for 
NS and LR infusions (Figure 3). The population mean (SEM) flow rates support this 
observation; the mean cumulative volume of fluid infused by each time point was 
similar for both solutions (Figure 4A). Mean (SD) infusion times for NS and LR solu-
tions (500 mL) were also similar (86.0 [29.8] vs 83.9 [28.0] min, respectively). 
Although Figure 4A gives the appearance of a slowing of the flow rate at later time 
points, this is an artifact of the progressively diminishing number of subjects at the 
later time points. Because the faster infusions had ended, only the slower infusions 
were left to contribute to the means.
Figure 4B illustrates the mean normalized infusion flow rates for NS and LR solutions, 
confirming that the subcutaneous flow rates remained relatively constant over time.
Thigh Circumference
The difference in mean (SD) thigh circumference between the NS and LR solutions 
was not statistically significant at baseline (57.4 [4.5] vs 57.5 [4.6] cm, respectively). 
Similarly, there was no significant difference between the solutions in either the maxi-
mal postbaseline thigh circumference (60.3 [4.3] vs 60.5 [4.5] cm, respectively) or the 
maximal percentage increase from baseline in thigh circumference (5.2% [1.6%] vs 
5.3% [1.5%]) (Figure 5).
Twelve of the 30 infusions (40%) resulted in an increase of ≥5% from baseline in 
thigh circumference. Among these, 7 (58%) were NS infusions and 5 (42%) were 
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LR infusions. The mean (SD) time required for thigh circumference to return to within 
5% of baseline for the NS and LR infusions was 147.3 (35.6) versus 123.5 (9.7) minutes, 
respectively. Descriptive statistics suggest the return to near-baseline thigh circumfer-
ence may have been slower for NS versus LR infusions; however, paired statistical 
analyses could not be performed for this end point because only 4 subjects (27%) had 
a ≥5% increase in thigh circumference for both infusions.
Global Preference
All 15 subjects (100%) expressed a global preference for the LR infusion over the 
NS infusion.
Safety and Tolerability
All 15 subjects (100%) experienced ≥1 mild AE, and 5 (33%) experienced a mod-
erate AE. No serious or severe AEs were reported. No subject had the study drug 
injection or NS or LR infusion prematurely terminated, and no subject was prema-
turely withdrawn from the study. The infusions were interrupted on 2 occasions, but 
neither of these was the result of an AE. In 1 case, the catheter required reinsertion 
after it slipped out during repositioning, which was performed to address a reduction 
in flow rate. In the other case, the interruption was due to leakage at the stopcock.
Of all AEs (regardless of their relationship to study drug or procedure), 81% were 
mild injection-site reactions that were similar in nature for the LR and NS solutions. 
Infusion-site reactions are summarized in the table. All were mild in severity, with 
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Figure 5.  Mean (SD) thigh circumference at baseline and maximal thigh circumference. 
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the exception of 2 reports of moderate local irritation, which occurred in the same 
subject. Although the types of mild local AEs were similar for the 2 infusions, they 
were numerically more common during NS infusions (15 subjects [100%]) than dur-
ing LR infusions (9 subjects [60%]). For the NS and LR solutions, the most frequent 
infusion-site AEs were pain (67% vs 40%, respectively), erythema (47% vs 13%), and 
irritation (27% vs 20%). Most local infusion-site reactions resolved within 24 hours 
of onset over a median time of 80 minutes, and all AEs resolved without sequelae 
within the 7-day observation period.
The mild, treatment-emergent AEs experienced by 15 subjects (100%) were 
considered to be related to the procedure (NS or LR infusion) in 14 subjects (93%), 
related to rHuPH20 in 8 subjects (53%), and related to both the study drug and 
the study procedure in 5 subjects (33%). The moderate treatment-emergent AEs 
experienced by 5 subjects (33%) were considered to be related to the study proce-
dure in 2 subjects (13%) and unrelated to the study drug or procedure in 3 subjects 
(20%).
Study drug–related AEs occurred in 8 subjects (53%). Injection-site erythema (as 
defined by the Medical Dictionary for Regulatory Activities Preferred Term list ver-
sion 1134), the most common drug-related AE in this study, occurred in 7 subjects 
(47%) (table). Injection-site pain and injection-site pruritus were each considered to 
be related to rHuPH20 in 2 subjects (13%). Procedure/infusion-related AEs occurred 
in the NS-infused thigh in 14 subjects (93%) and in the LR-infused thigh in 9 sub-
jects (60%). Except for 3 AEs in 2 subjects (13%) (moderate local irritation in both 
the NS- and LR-infused thighs in 1 subject; moderate headache in 1 subject), procedure/
infusion-related AEs were mild. Noninfusion-site AEs included 1 report each of 
peripheral edema (“swollen hands” beginning 21 hours after infusion completion and 
resolving after 30 minutes), pain, bronchitis, nasopharyngitis, tooth infection, and 2 cases 
of headache. Only 1 of these events (a single case of headache) was deemed to be re-
lated to the procedure, and none was considered to be related to rHuPH20.
Postbaseline assessment of vital signs, targeted physical examination, and measure-
ment of body weight revealed no clinically meaningful changes from baseline values.
Table.  Number (%) of adverse events (AEs) at the normal saline (NS)
solution and lactated Ringer’s (LR) solution infusion sites.
AE* NS (n = 15) LR (n = 15)
Pain 10 (67) 6 (40)
Erythema 7 (47) 2 (13)
Irritation 4 (27) 3 (20)
Pruritus 2 (13) 1 (7)
Bruising 1 (7) 0 (0)
* As defined on the Medical Dictionary for Regulatory Activities Preferred Term list 
version 11.34
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DISCUSSION
This first study to directly compare rHuPH20-facilitated subcutaneous administra-
tion of NS and LR solutions suggested that simultaneous infusions at 2 symmetric 
sites were generally well tolerated in these healthy adults. The subcutaneous infusions 
consisted of a total of 1000 mL per subject (500 mL of NS solution in 1 thigh and 
500 mL of LR solution in the contralateral thigh) and were completed, on average, in 
<90 minutes. Although individual subject-by-subject variations in infusion-site dis-
comfort were reported, no infusion had to be interrupted, slowed, or terminated as a 
result of drug- or procedure/infusion-related AEs. The mean maximal increase in VAS 
score between LR and NS infusions was well below the 25-mm threshold for study 
continuation.
While the mean maximal increases in postbaseline VAS of 20.0 mm and 9.4 mm 
for the NS and LR solutions, respectively, were small in relation to the possible VAS 
range of 0 to 100 mm—indicating that subcutaneous administration of both NS and 
LR solutions was generally well tolerated—the mean maximal increase from baseline 
in discomfort was statistically significantly greater with NS solution than with LR 
solution. Consistent with this observation, the incidence of some infusion-site AEs 
(especially pain, erythema, and irritation) was numerically greater with NS solution, 
and all subjects expressed a global preference for LR solution. These findings suggest 
that subcutaneous infusion of LR solution is better tolerated than NS solution, and 
this difference may be clinically meaningful.
Since there were no significant differences between solutions with regard to mean 
infusion flow rate or mean maximal change in thigh circumference, and the increases 
in thigh circumference were generally small, the difference in tolerability between 
subcutaneous infusions of NS and LR solutions may be related to an intrinsic property 
of the solutions, such as the lower pH of the NS solution.35,36 This hypothesis is sup-
ported by findings from another study comparing pain perception after subcutaneous 
injection of buffered formulations with small pH differences.36 In this double-blind, 
randomized study in healthy volunteers, the formulation with a slightly more acidic 
pH (6.0) was associated with significantly (P = 0.002) more pain immediately after 
subcutaneous injection compared with the formulation that was more alkaline (pH 6.15). 
Two minutes after the injections, there was no difference in pain perception with the 
2 formulations.36 
In general, the tolerability of rHuPH20 subcutaneous infusion in the present study 
was similar to that reported in previous publications. In the INFUSE-LR study,20 a 
randomized, double-blind, placebo-controlled, within-subject trial of 54 volunteers, 
the incidence of investigator-rated moderate or severe edema was significantly lower 
with rHuPH20-facilitated subcutaneous LR infusion than with subcutaneous LR in-
fusion alone (P < 0.003). All AEs were mild to moderate in severity, localized to the 
infusion sites, and evenly distributed between placebo and rHuPH20. In a retrospec-
tive chart review of hospice patients, pump-driven infusion of various solutions (NS, 
D5NS, and D51/2NS) also was generally well tolerated when facilitated with daily 
doses of 150 U of rHuPH20, permitting flow rates of 50 to 250 mL/h for up to 7 days 
without skin reactions at the subcutaneous sites after injection of rHuPH20, despite 
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repeated dosing.31 With the exception of 1 case of induration at the subcutaneous site 
after 7 days of therapy, there were no reported infusion-site AEs or skin reactions re-
lated to the repeated administration of rHuPH20.
As with any pilot study, conclusions from this trial are limited by the small sample 
size. The study enrolled a relatively homogeneous study population in regard to race 
and gender: the majority of the subjects were white women. Furthermore, the study 
was not designed with placebo controls for the 2 infusions; therefore, any interaction 
of rHuPH20 with NS solution or LR solution that might have contributed to the 
difference in pain perception between the 2 infusion solutions could not be detected 
using this study design. Future trials with a larger, more diverse study population and 
subcutaneous placebo and intravenous controls would be needed to identify the clini-
cal relevance of these outcomes. In addition, future studies would need to be designed 
to compare the tolerability of rHuPH20-facilitated subcutaneous administration of 
solutions with greater differences in pH and osmolarity and to clarify the importance 
of these variables on patient acceptance of subcutaneous administration of parenteral 
fluids and drugs.
CONCLUSIONS
This small pilot study found that the mean maximal increase from baseline in self- 
assessed pain VAS scores was statistically significantly higher in the group receiving 
NS solution than the group receiving LR solution. In addition, all subjects preferred 
LR solution to NS solution, and the incidence of some infusion-site AEs was numeri-
cally greater with NS solution. Although the VAS score indicated a statistically signifi-
cant difference in tolerability favoring LR, the modest changes from baseline suggest both 
solutions were generally well tolerated and support the use of both NS and LR, as appro-
priate, for rHuPH20-facilitated subcutaneous isotonic fluid infusion in healthy adults.
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